BJA ANNUAL GENERAL ASSEMBLY MEETING
Tuesday 19 March 2019
The President and the Board of Directors would like to invite you hereby to the Annual General Meeting of the BJA, that will be held on Tuesday, March 19, 2019 at 16:00, at KPMG/K law in Zaventem.
ãã®åº¦ãBJAã§ã¯å®ä¾ç·ä¼ã2019å¹´ã3æ19æ¥(ç«)ã16æããKPMG/K lawç¤¾ã«ããã¦ä¸è¨ã®è¦é ã§éå¬ãããã¾ãã®ã§ãæ¯éãåºå¸ä¸ããã¾ãããããæ¡å
We will deliberate on the following agenda:
1. Report by the President
2. Approval of the financial results for 2018
3. Approval of the 2019 budget
4. Report of the Committees
5. Statutory nominations
The General Assembly will be followed by Networking Cocktails offered by KPMG/K law,
preceded by a presentation by Dr Denis Lacombe, EORTC Director General, and Dr Mitsumi Terada,
EORTC Medical research fellow, about the partnership of EORTC and its Japanese counterpart.
2. 2018å¹´æ±ºç®å ±å
4. åå§å¡ä¼å§å¡é·ããå§å¡ä¼æ´»åå ±å
ç·ä¼å¾ãæ¬§å·çç ç©¶æ©é¢(EORTC)ãæé·ã®Lacombeåå£«ã¨ç ç©¶å¡ã®å¯ºç°åå£«ããã
15h30 Registrations and coffee/drinks
16h00 Start of Annual General Meeting and welcoming by Mr Koen Maerevoet, CEO of KPMG Belgium
17h00 Presentation by Dr Denis Lacombe, EORTC* Director General, and Dr Mitsumi Terada,
EORTC Medical research fellow, on: A partnership between EORTC
(European Organisation for Research & Treatment of Cancer) & JCOG (Japan Clinical Oncology Group)
- Improving survival and quality of life of cancer patient by accelerating process in surgical oncology.
17h20 Networking cocktails kindly offered by KPMG/K law
18h30 Evening adjourns
16h00 å®ä¾ç·ä¼éå§ãKPMGãã«ã®ã¼ãCEOã®Koen Maerevoetæ°ãããæ¨æ¶
17h00 æ¬§å·çç ç©¶æ©é¢(EORTCãæé·ã®Lacombeåå£«ã¨ç ç©¶å¡ã®å¯ºç°åå£«ããã
17h20 KPMG/K lawç¤¾æä¾ã®ã«ã¯ãã«
*EORTC (www.eortc.org) is a unique pan-European clinical cancer research organisation established in 1962 operating as an international non-profit association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. EORTC research network consists of over 5500 researchers and doctors from all disciplines involved in cancer treatment and research in more than 930 university hospitals in 27 countries. Its research spans the entire spectrum from translational and preclinical research to large, prospective, multi-centre, phase III clinical trials that evaluate new cancer therapies and/or treatment strategies as well as patient quality of life. Currently, EORTC is conducting 203 studies, and thousands of patients (85% from within the EU) participate in EORTC clinical trials. 25,000 patients continue to be followed on a yearly basis and the EORTC clinical study database now contains outcome data for over 190,000 cancer patients.
*EORTCã¯1962å¹´ã«è¨ç«ãããæ¬§å·æå¤§ã®è¨åºç ç©¶çµç¹ã§ããã«ã®ã¼ã®æ³å¾ã«æºæ ããéå¶å©å£ä½ã§ããEORTCã¯ããã®æ²»çæç¸¾ãæ£è
ããã®QOLï¼Quality of Lifeï¼çæ´»ã®è³ªï¼ãåä¸ããããããè³ªã®é«ããã©ã³ã¹ã¬ã¼ã·ã§ãã«ãªãµã¼ãï¼æ©æ¸¡ãç ç©¶ï¼ãè¨åºç ç©¶ã®éçºã»éç¨ã»èª¿æ´ã»ä¿é²ãæ
ã»å»å¸«ã5500äººä»¥ä¸ãåå ãã¦ãã¾ããEORTCãæ±ãç ç©¶ã®ç¯å²ã¯åºãããã©ã³ã¹ã¬ã¼ã·ã§ãã«ãªãµã¼ããåè¨åºç ç©¶ããå¤§è¦æ¨¡ãªå¤æ½è¨ååãç¬¬IIIç¸è©¦é¨ã«ã¾ã§åã³ã¾ãããããã£ãç ç©¶ãéãã¦æ°ããªããã®æ²»çæ³ãæ²»çæ¦ç¥ã®éçºãæ£è
ã¯EUå çå½ããï¼ãè¨åºç ç©¶ã«åå ãã¦ãã¾ããæ´ã«è©¦é¨çµäºå¾ã25000äººãã®æ£è
ããã®ãã¼ã¿ãå¤§åã«ä¿ç®¡ããã¦ãã¾ããè©³ç´°ã¯EORTCã¦ã§ããµã¤ãããè¦§ãã ããã www.eortc.org